Steven Silverstein, MD
Ophthalmology · Kansas City, MONPI 1285622951
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $585,162 of the $872,237 with a category attached, or 67.1%. 40 manufacturers reported payments, led by Mallinckrodt Hospital Products Inc. at 56.6% of the total. Among ophthalmology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,449 payments — averaging $601.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$494K
- Mallinckrodt Enterprises LLC$71K
- Bausch & Lomb Americas Inc.$60K
- Sun Pharmaceutical Industries Inc.$47K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$40K
- Omeros Corporation$37K
- plus $124K from 34 others
Across 136 payments — averaging $6336.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$399K
- Novartis$189K
- Bausch Health US, LLC$176K
- Omeros Corporation$35K
- Alcon Research LLC$23K
- Kala Pharmaceuticals, Inc.$21K
- plus $19K from 6 others
What the payments were for
- Consulting fees$126,68515%
- Speaking & faculty fees$585,16267%
- Grants$11,1251%
- Travel & lodging$98,52711%
- Food & beverage$49,4136%
- Education$1990%
- Gifts$1,1260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTHAR$558,947
- enVista MX60 IOL$64,679
- Crystalens Accommodating IOL (AT-52AO)$64,563
- Trulign IOL$64,563
- STELLARIS ELITE$48,338
- OMIDRIA$36,316
- Akreos AO IOL$35,292
- CEQUA$23,329
- BROMSITE$21,190
- DEXTENZA$20,103
- TRYPTYR$18,559
- STELLARIS$17,172
- ENVISTA$15,897
- STELLARIS PC$15,774
- CRYSTALENS$15,774
- AKREOS AO$15,774
- TRULIGN TORIC$15,774
- EYSUVIS$9,874
- DEXYCU$9,454
- Travoprost Intraocular Implant - iDose$8,168
How this compares
$872,237 in reported general payments places this provider in the 95th percentile of 286 ophthalmology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Acthar SelfjectCorticotropin | 21 | $1,064,694 |
| ActharCorticotropin | 18 | $1,028,500 |
| CortrophinCorticotropin | 13 | $417,133 |
| LumiganBimatoprost | 477 | $244,031 |
| RestasisCyclosporine | 115 | $129,620 |
| RocklatanNetarsudil Mesylat/Latanoprost | 133 | $63,786 |
| Cyclosporine | 74 | $45,129 |
| CombiganBrimonidine Tartrate/Timolol | 91 | $39,832 |
| Prednisolone Acetate | 1,092 | $39,783 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 162 | $34,867 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 94 | $34,679 |
| RhopressaNetarsudil Mesylate | 58 | $26,152 |
| XiidraLifitegrast | 25 | $19,956 |
| Ketorolac Tromethamine | 908 | $17,780 |
| VyzultaLatanoprostene Bunod | 48 | $16,942 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mallinckrodt Hospital Products Inc.Acthar | $493,843 | $1,028,50018 claims |
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $12,164 | $429,264735 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $614 | $89,939191 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $60,088 | $36,89873 claims |
| AlconSimbrinza | $23,458 | $34,67994 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate, Prolensa | $39,743 | $34,239162 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $46,515 | $11,73216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 286 ophthalmology providers in Missouri.
Other ophthalmology in Kansas City
- Joseph TauberKansas City$174K
- Stephen WilesKansas City$13K
- Michelle BoyceKansas City$10K
- Abraham ParkKansas City$6K
- Lindsey McDanielKansas City$5K
- Ranjan MalhotraSaint Louis$809K
- Nancy HolekampChesterfield$768K
- Jay PeposeChesterfield$516K
- Gregg BerdySaint Louis$360K
- Joseph GiraDes Peres$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.